Daiwa Pharmaceutical makes presentation on usability of "Rice Kefiran" for metabolic syndrome prevention at the 11th Journal of Japanese Association for Dietary Fiber Research


The 11th Journal of Japanese Association for Dietary Fiber Research sponsored by the Japanese Association for Dietary Fiber Research was held at Kanto Gakuin University on November 17 and 18. Mr. Hisayoshi Kato, manager of the Research and Development Department at Daiwa Pharmaceutical Co., Ltd. (Setagaya-ku, Tokyo, Japan; President, Yasuo Ninomiya) gave a presentation on Phytogalactoglucan from LK-Lactobacillus culture with rice medium, gRice Kefiran,h which will become Daiwa's 3rd flagship product after BioBran and NKCP.

gRice Kefiranh is a lactobacillus product obtained from kefir, a traditional fermented milk product of the Caucasus, a region famous throughout the world for the longevity of its people. The kefir-derived lactobacillus is singly cultured in a hydrolysis medium of grice,h the staple food of Japanese, and compared to existing kefir, is unique in its higher content of viscous polysaccharide, gkefiran.h gKefiran,h also a soluble dietary fiber, has long attracted attention for its functionality.

Daiwa's presentation on this occasion was entitled gThe Mechanism and Functionality of Viscous Polysaccharide, Kefiranh and presented the outcomes of the cooperative research by Dr. Tomotari Mitsuoka Ag (Professor Emeritus at the University of Tokyo) and Dr. Shinichi Kitamura (Professor at Osaka Prefecture University).

The following research results that were announced suggest that kefiran is a promising functional food material for the prevention of metabolic syndrome.
  1. When kefiran was orally administered to spontaneously diabetic KKAy mice at doses of 100 mg/kg and 300 mg/kg for 30 days, post-meal blood glucose was suppressed.
  2. By orally administering kefiran to SD rats fed a low-fiber diet for 3 weeks to induce constipation at doses of 100 mg/kg and 300 mg/kg for 14 days, dose-dependant intestinal function was confirmed.
  3. When kefiran was administered to stroke-susceptible, spontaneously hypertensive SHRSP/Hos rats raised on high-fat diets for 30 days and serum lipids were measured, decreases in total lipids, total cholesterol, and triglycerides were recognized in comparison to the control group.
gRice Kefiranh began to be supplied from July and already inquiries about new product development in soft drinks and supplements are increasing.

E

Copyright(C)2006 Daiwa Pharmaceutical Co.,Ltd. All rights reserved. | HOME >